Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | 212Pb-ADVC001 |
Synonyms | |
Therapy Description |
212Pb-ADVC001 is a radioligand therapy comprising ADVC001, a PSMA-targeting small molecule ligand, linked to the radionuclide 212Pb, which potentially induces antitumor activity (J Nucl Med 65 (supplement 2) (Jun 2024): 242474). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
212Pb-ADVC001 | 212Pb-ADVC001 is a radioligand therapy comprising ADVC001, a PSMA-targeting small molecule ligand, linked to the radionuclide 212Pb, which potentially induces antitumor activity (J Nucl Med 65 (supplement 2) (Jun 2024): 242474). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05720130 | Phase Ib/II | 212Pb-ADVC001 | Dose Escalation and Efficacy Study of 212Pb-ADVC001 in Patients With Metastatic Castration Resistant Prostate Cancer. | Recruiting | AUS | 0 |